This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: ‘COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs..., Annals of the Rheumatic Diseases, February 2021, Elsevier,
DOI: 10.1136/annrheumdis-2020-217738.
You can read the full text:
The following have contributed to this page
